Angelika Mattigk

KIM-1 in oligometastatic ccRCC. KIM-1 and ctDNA are independently prognostic. @DrChoueiri @VincentWenxinXu @PavlosMsaouel @lilli_ash @Clara__Steiner #GU26 @EUplatinum @ASCO @OncoAlert

There has been a lot of data on ctDNA in bladder cancer #GU26, but less on tumor DNA in the urine (utDNA). In this informed utDNA analysis from NIAGARA we show extensive utDNA positivity at baseline & clearance with neoadjuvant therapy. There is also a better correlation with utDNA and pCR than with ctDNA. This dual approach helps determine the origin of thr MRD (local vs systemic). False positive rates at CR need addressing. Clearance could be a marker of local therapy activity #GU26 @MichvdHeijden @MattGalsky

ASCO GU 2026 – Top 15 Trials with Potential Practice Impact @ASCO #GU26

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26

R3 LITESPARK-022: Adjuvant Pembrolizumab + Belzutifan vs Pembrolizumab for Clear Cell Renal Cell Carcinoma #GU26 showed significantly delayed DFS HR 0.72 (95% CI, 0.59–0.87) active across all subgroups. Immature OS (30 mnth OS 93% CDs 96%). ⬆️ Anaemia fatigue and transaminitis but only 4% discontinuation rate for belzutifan. The shape of the DFS curve and early OS trending the right way looks like initial analysis of KN564 and we know where that ended, making pem/bel attractive. @OncoAlert @DrChoueiri

Breaking news from @ASCO #GU26 👉Adding belzutifan to adjuvant pembrolizumab significantly improves disease free survival (HR: 0.72)👉Congrats @drchoueiri & team for changing SOC again in pts with #kidneycancer @kidneycan @OncoAlert @urotoday

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU clinical trials in 2025! 1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%. @tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO nejm.org/doi/full/10.10…

Superstar panel of mentors AND mentees at the young investigators panel this morning! #IKCSEU25

@BradLeibovichMD envisions the future of RCC surgery including computer vision, in vivo histology, personalized systemic therapy, anesthesiology and ambulatory care and…nanobots to replace surgeons !!! #EIKCS25 #IKCSEU25

From the March issue: Tracking Non-Genetic Evolution from Primary to Metastatic Clear Cell Renal Cell Carcinoma: #TRACERx Renal brnw.ch/21wRr47 By @Sanroman_Fern, @fendler_annika, @TurajlicLab, and colleagues @TheCrick @CNIOStopCancer @ChariteBerlin

🙌 Great group to welcome us to #IKCSEU25 today!

Micro-ultrasonography-guided biopsy is noninferior to MRI-guided fusion biopsy for the detection of clinically significant prostate cancer in biopsy naïve men. ja.ma/4hzTwTo #EAU25 @JulianStruck @moisessocarras @ChrisFungMD @arvinkgeorge @TxetxuPereira

Feeling truly proud today. Just yesterday we were talking about how important it is to see ourselves reflected on stage and in the OR—and today, watching @albasierraD, who was once my resident, perform live surgery at #EAU25, is both powerful and deeply moving. Female surgeons leading the way in front of an international audience—this is what representation looks like. #WomenInUrology #EAU25 #LiveSurgery #Mentorship #Inspiration

NIAGRA: neoadjuvant gem/cis +/- perioperative durvalumab shows significant OS and EFS. #GU25 @MattGalsky now shows the prognostic relevance of pCR. It also showed the durvalumab outperforms the control arm irrespective of pCR. @OncoAlert

Neoadjuvant disitimab Vedotin/toripalimab in 47 pts in UC. Cystectomy data on 33/47 as 14 didn’t have surgery. 21/33 surgery pts had pCR (63%) (45% of the ITT). NIAGARA had 37% in ITT, but a ⬆️% had surgery. We need a unified evaluation pCR evaluation compared to cCR etc #GU25

Extended follow up for Enfortumab/pembro in 1st line advanced UC (m 26mnths). PFS and OS HRs 0.48 & 0.51 respectively. Median duration of response is 2 yrs for the 68% who responded. The 30% with CR have75% & 95% 2 year PFS and OS respectively. Overall G3+ AEs 56 vs 57 % #GU25

TROPICS4 sacituzimab govitecan vs chemo in pretreated UC @Annals_Oncology OS & PFS HRs=0.86. RR 23 vs 14, but G3+ TRAE 67 vs 35% with ⬆️ G5 TRD. While there is activity the ⬆️ tox & lower RR compared to EV/erda was problematic. Phase 2 Data on 2 other TROP2/TOPO1 ADCs #ASCOGU25

1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin #CatherineWu @DanaFarber nature.com/articles/s4158… @DanaFarber_GU @OncoAlert @DFCI_NeoVax

TALAPR02 looks at Talazoparib/enza vs enza in 1st line CRPC . It has significant OS in ITT HR=0.796. It’s current used in HRR deficient. Subset analysis and wider data still supports the HRR biomarker OS (HRR deficient HR -0.54, HRR non-defficent/NA 0.87), but ITT OS is +ve #GU25